The high-stakes race to engineer new psychedelic drugs

Is this the start of 'Big Neuropharma'? As knowledge about the positive effects of psychedelic therapies goes mainstream, pharmaceutical companies are rushing to create patentable versions of hallucinogens. Here, John Semley questions if this is the beginning of a new era for mental health treatments or nothing more than a bad trip.